We will be discussing the 3 articles on sodium excretion, hypertension and mortality that were published in the NEJM on August 14 at 9pm. PBFluids has an early summary. Look for more background and links in the coming days.
Storify of Tuesday's TwitterChat
Tejas Desai of Nephrology On-Demand curated the chat into a tight Storify.
NephJC #9 is in the can
Great tweet chat tonight. Here are the analytics and the transcript. Look for a curated (Storify) transcript in a day or two.
Tweet of the (last) Week
Every so often a single tweet neatly encompasses the entire discussion. This happened at last week's aPLA2R TweetChat. This is the tweet that won:
But to properly set it up you need to additional tweets:
I love the idea of aPLA2R as a viral load, a leading indicator of idiopathic membranous nephropathy. Nice work Christos. For your effort we will be sending you a #NephJC coffee mug.
Want your own NephJC coffee mug?
Tweet better!
Next opportunity is tonight 9pm Eastern.
The Storify overview of #NephJC 8: aPLA2R
Once again we have two curated archives of the discussion. Joel Topf just published his version for NephJC:
And Tejas of Nephrology On-Demand once again published his curation:
aPLA2R Tweetchat, by the numbers
The August 12 Tweetchat went well with broad participation.
Tonight's NephJC Tweetchat is all about aPLA2R
aPLA2R is the first blood test specifically for nephrotic syndrome. It has recently been licensed by the FDA and we want to have an open and frank discussion on how this test may be used in clinical medicine. To aid in this discussion we will be looking at two papers.
The first was highlighted by CJASN's eJC and was covered summarized by Joel Topf and his Fellow, Bilal Saleem:
- Article Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy
- eJC forum
- Background and Summary by Topf and Saleem
- Make sure you take a look at the Editorial by Glassock (available for free if you register with eJC)
- PDF slide show summary of the article and editorial
The second article was published this past Spring in NDT. It is an industry sponsored trial of ACTH for the treatment of membranous nephropathy. Swapnil Hiremath summarized it for #NephJC
- Article (#OpenAccess)
- Background by Hiremath
- PDF of summary
And additionally here is a link to the KDIGO Glomerulonephritis Recommendations.
Please join us on Twitter at 9pm Eastern Daylight. Use the hashtag #NephJC.
FOAMED Student blog covers Nephrology
Pubmed Commons comment up for Meso-American Nephropathy
A bit belatedly, the pubmed comment is up from the great discussion from July 8th on MesoAmerican Nephropathy here.
NephJC made the FOAM Reduction e-mail mailing list
FOAM Reduction bills itself as a Twitter-free means of receiving FOAM (free open access medical education). The July 25th edition touched on the recent hyponatremia guidelines and included a shout out to our TweetChat. We are honored.
“Hyponatremia
Rumor has it that hyponatremia is near the top of UpToDate’s most searched list. Probably because it is so damn common (15-20% of hospital admissions) and the algorithm is a pain. Enter the Hyponatremia Guideline Development Group (I want to party with these guys), who recently published a new clinical practice guideline for diagnosis and treatment of hyponatremia. It is surprisingly easy to follow, by eliminating volume status guesses and depending on urine osmolality, urine sodium to determine the etiology of water excess.
The guideline can be found here and if you want a more expert take on the guidelines, a group of nephrologists performed a Twitter-based journal club (#NephJC, @nephjc) dissection on the guideline here.
I included the diagnosis algorithm from the new guideline below, along with the algorithm I see used most often.”
Storify of our RIVUR trip
RIVUR Tweetchat analytics
Our newsletter just went out and it is a doozy
Did we mention we had a news letter? (please sign up)
If you were on the mailing list, you can see the letter here. The e-mail covers three important pieces of NephJC news
1
Our next TweetChat is next Tuesday at 9 PM. We are looking at the NEJM article about VUR prophylaxis. Interesting paper. Pascal Lane did a wonderful summary of the study.
2
We are changing the way we do video interviews. These will no longer be scheduled events but, instead will get done when we can arrange a time with the most interesting scientists willing to talk to us.
3
We are exploring the possibility of doing a Live NephJC during Kidney Week in Philadelphia. We have a four question Survey Monkey to try to gauge how much interest there is in this idea.
NephJC.com user statistics
I have been a dedicated Mac user since 1991 and the turn around that Apple has pulled off never ceases to amaze me. Look at the OS distribution of readers of NephJC.com. Apple has 59% of visitors between iPhone and MacOSX. Incredible.
But I don't think all of the credit can be given to Stevie J and his merry band of Nexters. Look at the twin debacles of Vista and Win8. Together, those two OS's can't smell the OS share of XP whose latest update was over 6 years ago!
Nephrology On-Demand Storifies the Mesoamerican Nephropathy chat
Tejas continues to be a great supporter of the NephJC effort. He provides curated transcript to our latest Tweet Chat.
Pubmed Commons comment up for POSEIDON
The comment for the tweetchat of #NephJC 5, on the POSEIDON trial is belatedly up on PubMed Commons here.
Interesting toxin theory on the etiology of Mesoamerican Nephropathy
The investigators focused on how the disease emerged in the last 30 years and have tried to match chemical exposures to this time line and have come up with Monsanto's herbicide, Round-Up.
Here is the pubmed listing for the investigation
Possible NephJC article
An RCT in Hemodialysis patients that is positive? Where do I sign up!
Think JACC would make this open access?
MedPage Today helps promote #NephJC
Analytics from #NephJC 6
Great chat tonight with some notable new faces. Thanks for coming out.
